These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35711719)

  • 1. Response to Pralsetinib Observed in Meningeal-Metastatic
    Zhao Z; Su C; Xiu W; Wang W; Zeng S; Huang M; Gong Y; Lu Y; Zhang Y
    JTO Clin Res Rep; 2022 Jun; 3(6):100343. PubMed ID: 35711719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal Fluid Concentration of the RET Inhibitor Pralsetinib: A Case Report.
    de Jong LAW; Sparidans RW; van den Heuvel MM
    Case Rep Oncol; 2023; 16(1):1579-1585. PubMed ID: 38094038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined Dacomitinib and Selpercatinib Treatment for a Patient with
    Liu CY; Liu CH
    Onco Targets Ther; 2024; 17():499-506. PubMed ID: 38911906
    [No Abstract]   [Full Text] [Related]  

  • 4. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.
    Lin JJ; Liu SV; McCoach CE; Zhu VW; Tan AC; Yoda S; Peterson J; Do A; Prutisto-Chang K; Dagogo-Jack I; Sequist LV; Wirth LJ; Lennerz JK; Hata AN; Mino-Kenudson M; Nardi V; Ou SI; Tan DS; Gainor JF
    Ann Oncol; 2020 Dec; 31(12):1725-1733. PubMed ID: 33007380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP).
    Passaro A; Russo GL; Passiglia F; D'Arcangelo M; Sbrana A; Russano M; Bonanno L; Giusti R; Metro G; Bertolini F; Grisanti S; Carta A; Cecere F; Montrone M; Massa G; Perrone F; Simionato F; Guaitoli G; Scotti V; Genova C; Lugini A; Bonomi L; Attili I; de Marinis F
    Lung Cancer; 2022 Dec; 174():118-124. PubMed ID: 36379124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pralsetinib for the treatment of a
    Meng Y; Li L; Wang H; Chen X; Yue Y; Wang M; Meng L; Li B; Li X
    Ann Transl Med; 2022 Apr; 10(8):496. PubMed ID: 35571397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pralsetinib: A Review in Advanced RET Fusion-Positive NSCLC.
    Syed YY
    Drugs; 2022 May; 82(7):811-816. PubMed ID: 35587858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A non-small cell lung cancer (NSCLC) patient harboring a rare epidermal growth factor receptor (EGFR) L858R/V843I mutation complex benefited from osimertinib: a case report.
    Zhou Y; Qi X; Wang Y; Dong H; Zhuang L
    Ann Palliat Med; 2022 Mar; 11(3):1121-1125. PubMed ID: 35365042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report.
    Enrico D; Lacroix L; Chen J; Rouleau E; Scoazec JY; Loriot Y; Tselikas L; Jovelet C; Planchard D; Gazzah A; Mezquita L; Ngo-Camus M; Michiels S; Massard C; Recondo G; Facchinetti F; Remon J; Soria JC; André F; Vassal G; Friboulet L; Besse B
    JTO Clin Res Rep; 2020 Jun; 1(2):100023. PubMed ID: 34589930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pralsetinib treatment for multiple
    Cao X; Liu X; Wang S; Liu Z; Ren X; Sun D; Deng L
    J Int Med Res; 2022 Jun; 50(6):3000605221105368. PubMed ID: 35751411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pralsetinib: Treatment of metastatic RET fusion-positive non-small cell lung cancer.
    Nguyen L; Monestime S
    Am J Health Syst Pharm; 2022 Mar; 79(7):527-533. PubMed ID: 34864862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case report: Recurrent lung infections following treatment with pralsetinib for an elderly patient with
    An L; Chen P; Wang J; Qin X; Liu T; Gao Y; Wang P; Zhang D; Fang X; Zhang Z
    Front Oncol; 2022; 12():1024365. PubMed ID: 36568233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquired L718V/
    Schultz É; Pencreach E; Rimelen V; Palama A; Holder É; Gantzer J; Bender L
    Ann Transl Med; 2023 Mar; 11(5):223. PubMed ID: 37007549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osimertinib Quantitative and Gene Variation Analyses in Cerebrospinal Fluid and Plasma of a Non-small Cell Lung Cancer Patient with Leptomeningeal Metastases.
    Song Y; Liu P; Huang Y; Guan Y; Han X; Shi Y
    Curr Cancer Drug Targets; 2019; 19(8):666-673. PubMed ID: 30332963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durable response to low-dose pralsetinib in a renal insufficient patient with NSCLC harboring concurrent CCDC6-RET, LINCO1264-RET, and SEMA5A-RET fusions: A case report.
    Gu L; Ji W; Xu Y; Han Y; Jian H
    Medicine (Baltimore); 2022 Nov; 101(47):e31480. PubMed ID: 36451418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
    Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
    J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
    [No Abstract]   [Full Text] [Related]  

  • 17. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
    Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
    Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFR
    Park HR; Kim TM; Lee Y; Kim S; Park S; Ju YS; Kim M; Keam B; Jeon YK; Kim DW; Heo DS
    J Thorac Oncol; 2021 Nov; 16(11):1859-1871. PubMed ID: 34242789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient.
    Wang SS; Wang F; Zeng Z; Gao F; Liu HH; Wang HN; Hu Y; Qin HF
    Front Oncol; 2022; 12():929763. PubMed ID: 36226049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.
    Liu J; Jin B; Su H; Qu X; Liu Y
    BMC Cancer; 2019 Jul; 19(1):702. PubMed ID: 31315676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.